ArticleJournal of pharmacy & bioallied sciences2025
Enhancing Tuberculosis Diagnosis and Treatment Monitoring: Evaluating Ki67 and HLA-DR Biomarkers Via Point-of-Care Testing and Comparative Analysis of Flow Cytometry Versus ELISA in Whole Blood Samples.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Timely diagnosis and monitoring of tuberculosis (TB) remain critical challenges, especially in resource-limited settings. This study aimed to evaluate the diagnostic and treatment-monitoring utility of Ki67 and HLA-DR biomarkers in TB and to compare their quantification using flow cytometry and ELISA in whole blood samples. Methods: A total of 60 participants were enrolled, including 40 newly diagnosed TB patients and 20 healthy controls. Whole blood samples were analyzed at baseline, 2 months, and 6 months. Ki67 and HLA-DR expression were measured using both flow cytometry and ELISA. Statistical comparisons and agreement between methods were assessed using Pearson correlation and Bland-Altman analysis. Results: Both Ki67 and HLA-DR levels were significantly higher in TB patients compared with controls ( Conclusion: Ki67 and HLA-DR are promising biomarkers for TB diagnosis and treatment monitoring. ELISA provides a reliable, cost-effective alternative to flow cytometry, supporting its use in decentralized, point-of-care settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.